Purpose of review Disorders of sex development (DSD) are a diverse group of conditions affecting gonadal development, sexual differentiation, or chromosomal sex. In this review, we will discuss recent literature on the genetic causes of DSD, with a focus on novel genetic sequencing technologies, new phenotypes associated with known DSD genes, and increasing recognition of the role of genetic regulatory elements in DSD.
INTRODUCTION
Disorders of sex development (DSD) represent a heterogeneous group of 'congenital conditions in which development of chromosomal, gonadal, or anatomic sex is atypical' [1] . Over the past 30 years, we have learned much about the genetics of these disorders. By the late 1980s the human androgen receptor gene (AR) had been characterized [2] , and by the early 1990s the critical testis-determining region on the Y chromosome, SRY, was described [3, 4] . In the past two decades, the pace of genetic discovery has increased rapidly, with the identification of many new genetic causes of DSD. More than 50 genes have now been implicated in the pathogenesis of these disorders [5] . These genes encode essential factors in gonadal development or in sex-hormone synthesis or responsiveness (Fig. 1) .
The present review focuses on recent insights into the genetic causes of disorders of sex development and the use of innovative sequencing technologies to facilitate understanding of the pathogenesis and phenotypic spectrum of DSD. Recent reports in the DSD field have been in three areas: application of whole-exome sequencing (WES) to the identification of genetic causes of DSD, expansion of the observed phenotypes associated with variants in known DSD-associated genes, and an examination of the role of genomic regulation in human disease.
WHOLE-EXOME SEQUENCING IN GENETIC DIAGNOSIS OF DISORDERS OF SEX DEVELOPMENT
In the last decade, whole exome-sequencing (WES) has greatly improved our ability to identify diseasecausing genetic variants. WES is a method for sequencing all of the protein-coding regions (exons) of an individual's genome, which can then be compared to databases containing large numbers of control exomes to identify possible disease-causing variants [6] . Recently, this approach has been applied to individuals with DSD. Baxter et al. performed WES in 40 patients with 46,XY DSD who had not previously received a genetic diagnosis and identified pathogenic or likely pathogenic variants in known DSD genes in 35% of these patients ( Fig. 2) [7 && ].
NR5A1
Baxter et al. [7 && ] identified a pathogenic, heterozygous NR5A1 variant in one individual in the 46,XY DSD cohort who previously carried a clinical diagnosis of androgen insensitivity syndrome. NR5A1 (also known as steroidogenic factor 1, or SF-1) encodes a nuclear receptor expressed in the gonadal ridge as well as in Leydig cells later in gonadal development [8] . NR5A1 encodes a transcription factor involved in the formation of the bipotential gonad, which is also essential for the subsequent differentiation of the testis via several downstream factors including SOX9 (see discussion of this gene below) [8, 9] . Homozygous NR5A1 mutations are rare and cause complete gonadal dysgenesis as well as adrenal insufficiency, as NR5A1 also has a critical role in development of the adrenal cortex. In humans, heterozygous NR5A1 mutations are found in 10-15% of individuals with 46,XY DSD, but are not associated with adrenal insufficiency [10, 11] . 46,XY individuals with pathogenic heterozygous NR5A1 mutations may have a broad range of phenotypes ranging from isolated male-factor infertility [12] , to mild undervirilization with hypospadias and/or cryptorchidism, to severe undervirilization. Gonadal phenotypes range from normal to dysgenesis and anorchia [11] . Previous work has established that DSD gene mutations play a role in milder forms of undervirilization not typically classified as DSD, such as isolated hypospadias [10, 13] . Our group recently used WES to identify novel pathogenic NR5A1 mutations in two unrelated 46,XY individuals with bifid scrotum and penoscrotal hypospadias but not cryptorchidism [14 & ]. Additional novel phenotypes associated with NR5A1 mutations are discussed below.
WT1
Two subjects in the Baxter study had variants in WT1, which encodes a transcription factor involved in embryonic renal and gonadal development [7 && ]. Alternative splicing of WT1 RNA transcripts can result in more than 20 isoforms of the protein [15] .
Several phenotypes are associated with mutations in the WT1 gene. The most severe phenotype, 'WAGR' syndrome, is characterized by
KEY POINTS
Whole-exome sequencing has proven to be an effective modality by which to identify genetic causes of DSD, although its use has thus far been limited to a research setting.
An expanded understanding of the genetic variants associated with DSD phenotypes has brought about a deeper understanding of the biology of gonadal development. Wilms tumor, aniridia, genitourinary malformations (specifically undervirilization in 46,XY children), and intellectual disability. WAGR syndrome is caused by a deletion of the WT1 gene. Frasier syndrome in 46,XY children is caused by splice-site mutations in the WT1 gene, which alter the ratio of protein isoforms. Frasier syndrome is characterized by varying degrees of gonadal dysgenesis (partial to complete), renal failure later in childhood because of focal segmental glomerulosclerosis, and increased risk for gonadoblastoma. DenysDrash syndrome is caused by missense mutations affecting the zinc-finger DNA binding region of the WT1 gene, and is characterized by varying degrees of gonadal dysgenesis (partial to complete), renal failure early in childhood because of diffuse mesangial sclerosis, and increased risk for Wilms tumor and gonadoblastoma [16] . Isolated diffuse mesangial sclerosis has been attributed to WT1 mutations, in some cases with the same missense mutations that have been described in association with DenysDrash in other individuals [15, [17] [18] [19] .
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In the Baxter study, one patient with a WT1 variant presented with Müllerian structures and dysgenetic gonads bilaterally. On histology, the left gonad was consistent with an immature testis, and the right gonad contained fibro-fatty connective tissue with a possible vas deferens detected. This individual had end-stage renal disease and a previous history of bilateral nephrectomy, though no history of Wilms tumor. The second patient had cryptorchidism and a urogenital sinus, with bilateral testes, one with normal histology and one dysgenetic. There was no known renal disease in this patient, though medical records were incomplete [7 && ]. A recent report investigating genotype-phenotype relationships in a cohort of pediatric patients with steroid-resistant nephrotic syndrome identified WT1 mutations in 21 of the 354 patients (5.4%) [20 & ]. Of these subjects, 12 had a 46,XY karyotype, and all of these patients had a disorder of sex development, with eight having complete undervirilization of the external genitalia. The remaining four 46,XY subjects had partial undervirilization leading to hypospadias, with or without chordee and cryptorchidism. One 46,XY individual underwent gonadectomy at the age of 9 years and was found to have gonadoblastoma. Of the nine 46,XX individuals with WT1 mutations, one individual was found to have absence of ovaries, but DSD was not observed in the remaining eight individuals; later ovarian function was not reported.
Baxter et al. also identified genetic variants in several additional DSD-associated genes, including DHH, MAP3K1, and MAMLD1 (which are involved in testicular development), LHCGR (which encodes the LH/hCG receptor), AMHR2 (which encodes the anti-Müllerian hormone receptor), STAR and HSD17B3 (which are involved in testosterone synthesis), AR (which encodes the androgen receptor), and CHD7 (which is mutated in CHARGE syndrome, which includes genital anomalies among other features). These results highlight the utility of comprehensive genetic testing in the clinical setting to establish genetic diagnosis and in the research setting to expand our understanding of the frequency and phenotypic variability for specific genetic causes of DSD [7 && ].
A ROLE FOR NR5A1 IN OVARIAN FATE SPECIFICATION
As discussed above, NR5A1 has been thought to be chiefly involved in early gonadal development and testis determination. The majority of NR5A1 mutations associated with DSD to date have been identified in 46,XY individuals with varying degrees of undervirilization. Phenotypic manifestations of NR5A1 mutations in 46,XX individuals can include ovarian hypoplasia, premature ovarian insufficiency, and/or primary or secondary amenorrhea with otherwise normal urogenital structures. In some cases, fertility is preserved [21] .
Recently, two groups have described another phenotype associated with an NR5A1 variant in 46,XX individuals [ [25] , consistent with a role for NR5A1 in ovarian differentiation. The authors of both papers hypothesized that the variant identified in these cases disrupted NR5A1 activity in testis-opposing pathways in the developing ovary [23 && ]. Indeed, Bashamboo et al. specifically demonstrate that the Arg92Trp mutant NR5A1 protein exhibited less robust ability to synergize with b-catenin, a component of the Wnt signaling pathway, in promoting the expression of genes that inhibit testicular differentiation [22 && ]. An additional phenotype for NR5A1 mutations in 46,XY individuals was explored by Ferlin et al. They found a prevalence of 1.8% for heterozygous missense NR5A1 mutations in infertile males with severe impairment in spermatogenesis, with a higher rate of mutations (2.7%) in men with a prior history of cryptorchidism, as compared to 1.4% of men without cryptorchidism [26] . This report was comparable to previous reports that identified an NR5A1 mutation prevalence of 4% in a cohort with idiopathic male infertility because of failure of spermatogenesis [27] .
MUTATIONS IN THE REGULATORY REGION OF SOX9
Recent work in the field of DSD genetics has included an examination of the role of genetic regulatory elements in the pathogenesis of DSD, particularly involving the SOX9 gene. SOX9 is a target of SRY and is essential for testicular differentiation [28] . Loss-of-function mutations in SOX9 are a cause of 46,XY DSD, and large duplications near SOX9, hypothesized to be gain-of-function mutations, have been identified in patients with 46,XX DSD [29] [30] [31] . Studies in mice have identified specific enhancer regions required for the expression of SOX9 in early testis development [32] . Benko et al. had previously described five DSD cases associated with disruption of SOX9 regulatory regions. Three 46,XX individuals with virilization and ovotesticular DSD were found to have duplications in a regulatory region upstream of the SOX9 gene. Furthermore, two 46,XY individuals with gonadal dysgenesis and severe undervirilization were found to have deletions in the same region. Based on the location of the duplications and deletions discussed above, the authors hypothesize the existence of a 517-595 kb regulatory region upstream of SOX9 that when duplicated may drive a testicular fate for the bipotential gonad in 46,XX individuals, possibly through modification/relaxation of epigenetic repressors. When deleted in 46,XY individuals, SOX9 expression is restricted, leading to impaired testicular development [33] .
Hyon et al. describe three males with phenotypically normal male genitalia who presented with infertility and were found to have low testicular volume and azospermia. On further evaluation, all three cases had 46,XX karyotypes and duplications upstream of the SOX9 gene overlapping with the region described by Benko et al. The authors were able to identify a smaller minimal critical regulatory region of 40-41.9 kb located 600 kb upstream of SOX9, which, when duplicated, may be sufficient to induce testicular differentiation in 46 
CONCLUSION
Facilitated by ongoing developments in genetic sequencing technologies, advances continue to be made in understanding the genetics of DSD and, in turn, the biology of gonadal development. Recent findings have mostly focused on previously identified DSD genes; future work will undoubtedly use WES and other emerging technologies to identify new DSD genes.
WES is becoming increasingly available in the clinical setting, and the ability to provide genetic diagnoses for a large fraction of DSD promises to change the way we advise and treat patients with these conditions. For example, establishing a specific genetic diagnosis may allow for improved guidance on oncologic risk and early identification of associated issues such as renal insufficiency. As the pace of innovation in genetic diagnosis continues to accelerate, the impact of WES and related methods on patient care will be an essential area of future inquiry.
